7JZL

SARS-CoV-2 spike in complex with LCB1 (2RBDs open)

7JZL の概要

• エントリーDOI: 10.2210/pdb7jzl/pdb
• EMDBエントリー: 22532
• 分子名称: Spike glycoprotein, LCB1, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
• 機能のキーワード: sars-cov-2, covid-19, spike glycoprotein, fusion protein, neutralizing antibodies, structural genomics, seattle structural genomics center for infectious disease, ssgcid, inhibitor, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 460090.26

構造登録者

Park, Y.J.,Veesler, D.,Seattle Structural Genomics Center for Infectious Disease (SSGCID) (登録日: 2020-09-02, 公開日: 2020-09-23, 最終更新日: 2020-11-04)

• 主引用文献: Cao, L.,Goreshnik, I.,Coventry, B.,Case, J.B.,Miller, L.,Kozodoy, L.,Chen, R.E.,Carter, L.,Walls, A.C.,Park, Y.J.,Strauch, E.M.,Stewart, L.,Diamond, M.S.,Veesler, D.,Baker, D.; De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.; Science, 370:426-431, 2020; PubMed: 32907861; DOI: 10.1126/science.abd9909

実験手法